Please login to the form below
Gilead Sciences in US investigation
Gilead Sciences is having its manufacturing and distribution practices investigated by the US Attorney's Office
Gilead Sciences has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices of its HIV and hepatitis B drugs.
The subpoena involves the drugs Atripla (efavirenz tenofovir emtricitabine), Emtriva (emtricitabine), Hepsera (adefovir dipivoxil), Letairis (ambrisentan), Truvada (tenofovir emtricitabine), Viread (tenofovir) and its investigational fixed-dose combination of Truvada and Edurant (rilpivirine).
In a statement the company said it is cooperating with the civil and criminal investigation.
The case could take years to resolve and is likely to result in a substantial fine.
Share
Related Hub content
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
